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ABSTRACT 
Objective: The aim of this study was to formulate ketoconazole (keto) as oral floating in situ gel to slow the release of keto in the stomach. 
Methods: Sodium alginate (Na alginate) was used as a primary polymer in the preparation of the in situ gel and was supported by the following 
polymers: guar gum (GG), hydroxypropyl methylcellulose (HPMC) K4M, K15M and carbapol 940 as viscosity enhancing agents. As a consequence, 
and to complete the gelation process of above formulations was by adding the calcium carbonate (CaCO3
Results: The study showed that the faster release was obtained with F1 which contained Na alginate alone. Additionally, reduction in Na alginate 
concentration resulted in significant increase in drug release. It was also noted that the increase in GG (viscosity enhancing polymer) concentration 
resulted in non-significant decrease in percent drug release and the reduction in CaCO3 concentration led to significant increase in drug release. 
Moreover, the release of drug was also affected by grade of viscosity enhancing polymer, the faster release was observed with the formula which 
contained a polymer of low viscosity (HPMC K4M) and an opposite result was with the high viscosity polymer (HPMCK15M).  
). The in situ gels were investigated by the 
following tests: floating lag time, floating duration, viscosity, drug content, in vitro gelling studies and in vitro release study. 
Conclusion: This study showed the formulation of Na alginate with GG and CaCO3
Keywords: Ketoconazole, In-situ floating gel, Sodium alginate, Guar gum, HPMCK4M, HPMCK15M 
, led to gain floating in situ gel and a sustained release of keto.  




Recently, gastro retentive dosage forms (GDF) have been studied 
extensively by researchers due to their essential characteristic of 
staying in the stomach for prolonged period of time which enabled 
slowing and sustaining the release of the selected drug in the stomach 
[1]. Also, this distinctive characteristic of GDF helped in solving many 
problems were associated with pharmaceutical formulations such as 
the narrow window absorption of the upper part of the 
gastrointestinal tract, drugs with short half-lives, unstable drugs in the 
environments of lower segment of the gastrointestinal tract, drugs for 
local target activity in the upper region of gastric tract and the low 
solubility of specific drugs in the basic gastric pH [2]. 
The GDF can be prepared by different techniques such as the dosage of 
low density to gain floating delivery system or high density dosage 
form that retain the dosage form in the lower part of the stomach. 
Additionally, the GDF can be obtained by formulating an adhesion 
form to the stomach mucosa or in a different way by expansion the 
size of the formulation to delay the emptying from the upper part of 
gut or by using ion exchange resin to gain adherence to the stomach 
mucosa [3]. The in situ gel preparation is one of the GDF that provide a 
controllable drug release in the stomach. This preparation is gelled 
upon contact to the stomach content and floats on the stomach surface 
fluid due to the influence of excipients having a lower density than the 
stomach fluid [4]. These properties were as a guide for many 
researchers to develop formulations that increased the efficacy of 
many drugs such as Rajinikanth et al. who utilised amoxicillin as a 
model for in situ gelling and they found a better eradication of H. 
pylori in comparison with amoxicillin suspension [5]. This was due to 
the prolonged release in the stomach. Also, Darekar et al. prepared in 
situ gel incorporated with levocitrizine dihdrochloride to gain a 
prolonged release and to control the allergy symptoms [6]. In this 
current study, we focused on 
Also, it was reported that 90% of keto binds to plasma albumin and 
its elimination showed biphasic behaviour of 2 h and 8 h as initial 
and terminal half-lives respectively. Usually, keto is metabolised to 
an inactive metabolite in the liver as both the later and the 
unchanged form of a drug are excreted via the renal route [8]. 
keto due to its systemic importance in 
mycoses treatment as this drug is classified as a fungistatic. The 
antifungal mechanism is by inhibiting cytochrome P450 enzyme 
leading to block the demethylation of primary sterols of the fungal 
membrane. By the aid of this mechanism, a distortion of the 
membrane structure is followed to retard the fungus growth. Also, 
keto as antifungal is a broad spectrum, inhibits a plenty of gram-
positive bacteria and protozoa [7]. 
Additionally, keto is formulated for oral route and its absorption 
increases at stomach low pH [9]. A part of our work novelty and 
according to our knowledge, no study has investigated and 
formulated keto as in situ gel. This study used advantage of the 
increasing solubility of keto at the low pH of stomach as this 
guarantees a better bioavailability due to the slow release by the in 
situ gel. Thus, many studies have been done in this work to explore 
the in situ gel of keto such as determination of keto content in 
different formulations. Also, the examination of the in vitro of both 
gelation and floating and this is followed by viscosity measurements. 
These studies were supported by studying the effect of different 
concentrations of CaCO3
MATERIALS AND METHODS 
as a crosslinking and gas generating agent 
and polymer to polymer ratio of both the Na alginate and GG. 
Additionally, the effect of addition of different grade of HPMC in the 
presence of Na alginate on the release of keto was studied too. 
Materials 
Keto was purchased from (Shanghai Macklin Biochemicals Co. Ltd,. 
China), Na alginate and CaCO3
Methods 
 (Sinopharm Chemical Reagent Co., 
Ltd. China), GG (Samara Drug Industry, Iraq), HPMCK4M and 
HPMCK15M (Alladin Industrial Co., Shanghai, China), carbapol 940 
(Himedia lab., India.), Methyl paraben and propyl paraben (BDH 
Ind., India). 
Keto preparation as floating in situ gel 
Different compositions of Keto formulations of floating in situ gel as 
shown in table 1 were prepared by a gradual addition of Na alginate 
to a specific portion of water at 100 °C. This helps to solubilise Na 
alginate with the aid of stirring by using hot plate magnetic stirrer. 
Then this followed by addition of GG and in a different beaker, the 
parabens were dissolved in another portion of water at 100 °C. This 
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followed by addition of keto to the contents after mixing of the two 
beakers with continuous stirring and cooling. After 15 min of 
keeping as a waiting period for the preparation, the CaCO3
 
 was 
added with continuous stirring until a homogeneous dispersion was 
gained. This formulation was allowed to cool at room temperature 
with volume adjusting using water to 100 ml [10]. 
Table 1: The composition of keto in situ floating gel different formulas 
Formulation code 
ingredient (mg) 
F1 F2  F3  F4  F5 F6 F7  F8 F9 
Keto 2000 2000 2000 2000 2000 2000 2000 2000 2000 
Na alginate 2000 2000 1000 1000 2000 2000 2000 2000 2000 
GG ---- 500 500 500 500 1500 ---- ---- ---- 
CaCO 1000 3 1000 1000 500 2000 2000 1000 1000 1000 
Methyl paraben 90 90 90 90 90 90 90 90 90 
Propyl paraben 10 10 10 10 10 10 10 10 10 
HPMC k4 M --- --- --- --- --- --- 500 --- ---- 
HPMC K 15 M ---- --- --- --- --- --- --- 500 ----- 
Carbapol 940 ---- --- --- --- --- --- --- ---- 500 
D. W (ml) up to 100 100 100 100 100 100 100 100 100 
 
Evaluation of prepared keto in situ floating gel 
Physical appearance and pH 
All formulations were screened to check the presence of foreign 
particles or not. Also, the pH of all formulations was measured using 
a digital calibrated pH meter [11].  
Determination of drug content 
By the aid of sonication, a dissolved in situ solution was obtained 
by adding 10 ml of in situ solution to 0.1N hydrochloric acid 
(HCl) and then top up with 0.1N HCL to 100 ml. The keto content 
was measured by using UV-spectrophotometer (Shimadzu, 
Japan) at λ max
Viscosity measurement of the In-situ gelling solutions 
 270 nm and this needed a proper dilution using 
0.1 N HCl [6]. 
In vitro gelation study 
The capability of in situ solution to gel was evaluated visually by 
pouring 10 ml of the in situ solution to 100 ml of 0.1N HCl (pH 1.2). 
This was followed by watching and counting the time needed by in 
situ solution to be solid and for how long persisted intact where this 
technique was graded to 3 classes:  
(+)–Dispersed quickly within few minutes once gelation occurred. 
(++)-Persistent intact for 12 h after instant gelation. 
(+++)-Persistent intact for more than 24 h after instant gelation [12]. 
In vitro floating study 
This was executed in stagnant condition at 37 °C by pouring 10 ml of 
liquid formulations into 100 ml of 0.1N HCL contained in a beaker.  
This study assisted to evaluate firstly, the floating lag time which 
indicates the actual time for the gelling formulation to rise to the 
surface of media and secondly, the duration of floating which 
represents the period of floatation persistence [13]. 
Viscosity of the solutions of in situ gels was determined using a 
Brookfield digital viscometer. 50 ml of prepared solutions were 
sheared ata rate of 100 rpm/min using spindle number 2 at room 
temperature [14]. 
In vitro release study 
To evaluate the release of keto from in situ gel, 10 ml of in situ liquid 
was added to 900 ml of 0.1N HCl (pH 1.2) as this study was run at 37 
°C (body temperature) and stirring rate was 50 rpm to mimic the 
mild agitation of stomach and keeping formulation solid by using 
type II (paddle method) dissolution apparatus. A withdrawn sample 
of 5 ml was replaced by the same volume of fresh 0.1N HCL to keep 
the sink condition within time course of the study and filtered by 
Whatman filter paper. These samples were diluted then keto 
quantified at λmax
RESULTS AND DISSCUSSION 
270 nm [15]. 
Statistical analysis 
ANOVA test (one way analysis of the variance) was applied for 
statistical analysis. Significant statistical differences were 
considered when (p<0.05). 
Evaluation of ket floating in-situ gel  
In this current study, the formulations that contained keto for 
floating in situ gel were nine composed of Na alginate which is the 
main polymer that form gels. Additionally, GG, HPMC K4M, HPMC 
K15M and carbapol 940 were added to the solution of Na alginate to 
enhance its viscosity and to retard the release of keto upon gelation. 
Furthermore and to complete the gelation process, CaCOR3Rwas added 
which also act as a gas generating agent. The last one was used in 
different concentrations to optimise the concentration for better 
gelation. Different parameters were investigated for formulations 
(F1to F9) as demonstrated in table 2 and discussed in details below.
 
Table 2: Evaluation of keto floating in-situ gel 
Formulation code pH Gelation time  
(sec) 
Drug content Floating lag time (sec) Duration of floating 
(h) 
Viscosity (cp) 
F1 7.5 ++ 93.8±0.43 130±0.15 >12 336±0.33 
F2 7.75 +++ 94.3±0.23 138±0.19 >12  678±0.56 
F3 8.81 +++ 95.1±0.17 131±0.09 >12 473±0.3 
F4 8.81 +++ 92.33±0.1 139±0.13 >12 538±0.14 
F5 7.79 +++ 89.5±0.36 145±0.05 >12 574±0.26 
F6 8.34 +++ 95±0.3 157±0.2 >12 1360±0.1 
F7 8.1 +++ 90.9±0.21 133±0.2 >12 450±0.0.5 
F8 8.2 +++ 89.1±0.4 132±0.26 >12 511±0.22 
F9 --- --- ---- --- --- 1515±0.4 
(mean±SD, n=3) 
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Physical appearance and pH 
The nine formulations appearance was screened and found that all 
the liquid formulations were light brown, smooth and free from 
lumps or clots. 
Also, the pH was investigated to make sure that the formulation pH 
is far from acidic or basic pH that harms the throat [16]. As shown in 
table 2, the pH of the eight formulations was within this range (7.75-
8.81) which indicts a neutral or light alkaline pH and this is 
compatible with desired pH for oral formulations as no need for 
further pH adjustment [17].  
In vitro gelation time 
The process of gelation starts after the CaCOR3Rin liquid formulations 
being in contact with the acidic medium which is then followed by 
the release of gas and calcium ions. An instantaneous hardening to 
the liquid formulation occurs once the interaction happens between 
calcium ions and sodium alginate (the anionic polymer) giving a 
reservoir of three dimensional (3D) solid structure that slows the 
release of keto [18]. This was shown in table 2 where the gelation 
time study was executed using 0.1N HCl (pH 1.2). The results 
revealed that all formulations showed an instant gelation and 
staying as an intact 3D structure for more than 24 h except the F1 
that gelled instantly but remained intact not more than 12 h. This 
could be explained that F1 composed of just Na alginate and free 
from viscosity enhancing agent, thus F1 showed rapid vanishing and 
this might be owing to the Na alginate gel is a porous scaffold. 
Obviously, this scaffold permits an ease water entrance leads to 
speed up the gel dissolution [19].  
Drug content 
The uniform distribution of keto in the formulations was studied as 
shown in table 2 and it was found that the drug content within this 
range (89.1-95.1%). This was within the acceptable limits that are 
determined by USP (not<85% and not>115%) [20].  
In vitro floating study 
The buoyancy of the in situ gels is due to the presence of CaCOR3R 
which generates gas upon contact with the acidic medium which 
helps gels to float [21], and as the residence time of gels increased as 
this guarantees the absorption of drug in the stomach [22, 23]. This 
was investigated via in vitro study as shown in table 2. All 
formulations floated for more than 12 h and the longest floating 
period was 157 seconds for F6 whereas F1 showed the least floating 
time which was 130 seconds. 
Viscosity study 
The liquid gels formulations that contained the viscosity enhancing 
agent helps to gain an appropriate viscosity and permit an easy 
swallowing. Also, as these agents facilitate the solid gels formulations 
to be coherent and solid enough to slow the release of keto. 
The results of viscosity for formulations F1 to F9 were demonstrated 
in table 2 as F1 showed the lowest viscosity value 336 cp and this 
might be due to the F1 contained no viscosity enhancing agents. On the 
other hand, the F9 showed the highest viscosity value 1515 cp and this 
high value could be as a result of the presence of the carbapol 940. 
This made F9 non pourable and no further investigation was followed 
this study on F9. Generally, the formulation’s viscosity showed the 
following order F9>F5>F8>F7 that contained carbapol 940, GG, 
HPMCK15M and HPMCK4M respectively. Besides the impact of GG on 
the viscosity of in situ gels, increasing its concentration led to increase 
the viscosity of F5 and F6 and this might be as a result of the increase 
in the interaction amongst the polymers [24]. 
Also, it was noticed that the increase in the molecular weight of 
HPMC led to increase in the viscosity of the formulations as shown in 
F7 and F8. Another finding was the increase in CaCOR3R concentration 
led to increase in the viscosity and this might be due to the increase 
in the dispersed amount of CaCO3 through the whole formula which 
helped in more hardening to the Na alginate gels [25]. 
In vitro release study 
The release of keto was studied for 3 h for different formulations using 
USP paddle type apparatus. The keto concentration was calculated by 
the following equation of the calibration curve (y=2.43x+0.0341) 
which was constructed from serial dilutions of keto in 0.1N HCl 
solution (pH 1.2). These dilutions were read by spectrophotometer at 
λmax of keto which was 270 nm. The main polymer in this work is the 
Na alginate, thus the effect of different amounts of the main polymer 
was investigated using F1, F2 and F3 and it was found as shown in fig. 
1, the F1 released 99% (w/w) of keto within 30 min. This fast release 
referred to the low viscosity of F1and probably due to the lack of GG 
which in turn reflected the low solidity of the formulation upon 
gelation. As well and in the presence of 0.5% (w/w) of GG, a significant 
increase(p<0.05) in the release of keto was observed as the amount of 
Na alginate was reduced from 2% (w/w) (F2 around 49%) to 1% 
(w/w) (F3 around 58%) and as shown in fig. 1. This result was similar 
to the preparation of ranitidine in situ gels by Rohith et al. study as 
they increased the Na alginate concentration from 0.5% (w/w) to 1% 
(w/w), the release of ranitidine decreased from 96.5% to 74% within 
a frame time of 8 h respectively [26]. 
 
 
Fig. 1: Effect of Na alginate concentration on drug release (mean±SD, n=3) 
 
The effect of GG content was also studied as shown in fig. 2 and it 
was found a non-significant (p>0.05) decrease in the keto release of 
F5a 43% compared with 40% of F6after 180 min as changes in the 
concentrations of GG was 0.5% (w/w) and 1.5% (w/w) respectively. 
The role of the presence of another polymer besides the main 
polymer in the formulation of in situ gels was investigated by 
Maheswaran et al. They also found as they increased the HPMC 
content in Na alginate formulations as the release of diltiazem 
decreased [27]. This could be clarified that the presence of two 
polymers leads to increase the density of gelled formulations which 
consequently slows the diffusing molecule through this kind of 
matrix [24]. 
Jaafar et al. 




Fig. 2: Effect of GG concentration on drug release (mean±SD, n=3) 
 
Additionally and it was obvious the importance of CaCO3 in the 
gelation of Na alginate, hence the different contents of CaCO3 were 
investigated in F3 and F4. As shown in fig. 3, the release of keto 
decreased from 62% to 58% as the CaCO3 increased from 0.5% 
(w/w) to 1% (w/w) in F4 and F3 respectively. This could be made 
clear that the increase in the calcium ions due to the increase in the 
CaCO3
 
 content enhances sufficient crosslinking sites between 
sodium alginate molecules [28]. 
 
Fig. 3: Effect of CaCO3
 
 concentration on drug release (mean±SD, n=3) 
The clear impact of GG in retarding the keto release from Na alginate 
formulations was encouraging to investigate other polymers as 
viscosity enhancing polymers. This was done by choosing a base 
formulation containing 2% (w/w) Na alginate, 0.5% (w/w) GG as in 
F5, further to, selective polymers the HPMC K4M and the HPMC 
K15Mwere added as in F7 and F8 respectively. As shown in fig. 4, the 
slow release order of these formulations was in the following order 
F5>F8>F7 and significant (p<0.05) decrease in the release rate of 
keto as F5 compared with F8 and F8 compared with F7. This could 
be clarified on the base of the effect of polymer grade of HPMC on 
the release of keto which was observable and showed an inverse 
relationship. As well, Li et al. obtained the same finding and they 
found the high grade of HPMC K4M in combination with carbopol 
slowed the release of calcium as compared with the formulation of 
low grade of HPMC K100LV with carbopol [29]. 
Based on the above results, the prepared in situ floating gel of F3 
which showed pH 8.81, floating lag time of 131±0.09, floating 
duration of>12 and viscosity 4730 cp can be considered as the 
optimum formulation that met the aim of our work. 
 
 
Fig. 4: Effect of viscosity enhancing polymers concentration on drug release (mean±SD, n=3) 
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The enormous interest in studying the GDF was due to the ability of 
these formulations to stay in the stomach for a long time hence we 
focused in this work on the in situ gel formulation selecting the keto 
as a model. This was to study the capability of in situ gel formulation 
controlling the drug release and enhancing the solubility of keto in 
the stomach media. The results revealed that F1 showed 99% of 
keto released within 30 min which contained just Na alginate. Also, 
the reduction in Na alginate concentration in the presence of 0.5% 
w/w GG from 2% w/w as in F2 to 1% w/was in F3 led to increase 
the release of keto from 49% to 58% within 180 min respectively. 
Furthermore, it was found when the CaCO3
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